View Older Stories View More Recent Stories

Apr 6, 2020 07:00AM Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Apr 6, 2020 07:00AM Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Mar 30, 2020 04:15PM Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
Mar 30, 2020 04:15PM Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
Mar 30, 2020 06:07AM Esperion Therapeutics (ESPR) Reports Three Data Presentations of NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet
Mar 28, 2020 09:30AM Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual S
Mar 28, 2020 09:30AM Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual S
Mar 23, 2020 07:33AM Esperion (ESPR) Announces Presentation of Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL
Mar 23, 2020 07:30AM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimi
Mar 23, 2020 07:30AM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimi
Mar 18, 2020 07:37AM Esperion Therapeutics (ESPR) Announces Alan Fuhrman to Board
Mar 18, 2020 07:30AM Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
Mar 18, 2020 07:30AM Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
Feb 28, 2020 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2020 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2020 07:00AM Esperion to Participate in Upcoming Investor Conferences
Feb 28, 2020 07:00AM Esperion to Participate in Upcoming Investor Conferences
Feb 27, 2020 07:00AM Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 27, 2020 07:00AM Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 26, 2020 05:32PM Esperion Therapeutics (ESPR) Announces FDA Approval of NEXLIZET Tablet
Feb 26, 2020 05:30PM Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Feb 26, 2020 05:30PM Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Feb 21, 2020 04:38PM Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Feb 21, 2020 04:38PM Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Jan 31, 2020 07:05AM Esperion Therapeutics (ESPR) Reports Positive CHMP Opinion for MAA for Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Jan 31, 2020 07:02AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixe
Jan 31, 2020 07:02AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixe
Jan 31, 2020 07:02AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixe
Jan 31, 2020 07:01AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Jan 31, 2020 07:01AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Jan 31, 2020 07:01AM Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Jan 7, 2020 07:30AM Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 7, 2020 07:30AM Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 3, 2020 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 3, 2020 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 22, 2019 06:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 22, 2019 06:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 18, 2019 05:59AM Esperion Therapeutics (ESPR) Highlights Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid
Nov 17, 2019 03:05PM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
Nov 17, 2019 03:05PM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
Nov 12, 2019 11:07AM Esperion Therapeutics (ESPR) Announces Publication in JAMA of Bempedoic Acid Phase 3 Study 2 Results
Nov 12, 2019 11:05AM Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
Nov 12, 2019 11:05AM Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
Nov 7, 2019 07:30AM Esperion to Participate in Upcoming Investor Conferences
Nov 7, 2019 07:30AM Esperion to Participate in Upcoming Investor Conferences
Nov 6, 2019 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
Nov 6, 2019 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
Nov 4, 2019 07:32AM Esperion Therapeutics (ESPR) Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented AHS
Nov 4, 2019 07:30AM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
Nov 4, 2019 07:30AM Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
View More Recent Stories View Older Stories